RCS - Roquefort Theraptcs. - Investor Presentation via Engage Investor

Roquefort TherapeuticsAnnouncement

24/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250924:nRSX5229Aa&default-theme=true

RNS Number : 5229A  Roquefort Therapeutics PLC  24 September 2025

24 September 2025

 

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Investor Presentation via Engage Investor

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company,
announces that the Company's Chairman Stephen West alongside Edward Painter
and Sridhar Vempati, Chairman and Chief Strategy Officer respectively of A2A
Pharmaceuticals, Inc. ("A2A Pharma") will host a live interactive presentation
on the Engage Investor platform on Monday, 29 September 2025 at 4pm BST.

The objective of the presentation is to provide investors with an update
relating to the proposed acquisition of Coiled Therapeutics, Inc. and its
AO-252 clinical stage program from A2A Pharma.

All current shareholders and interested investors are invited to join and
investors are encouraged to pre-submit questions via the Engage Investor
platform. Investors can also submit questions at any time during the live
presentation.

Investors can sign up to Engage Investor at no cost and follow Roquefort
Therapeutics from their personalised investor hub.

Register interest in this event here:

https://engageinvestor.news/ROQ_IP_0925
(https://engageinvestor.news/ROQ_IP_0925)

ENDS

Enquiries:
 Roquefort Therapeutics plc                               +44 (0)20 3918 8633
 Stephen West (Chairman) / Dr Darrin Disley (Interim MD)
 SP Angel Corporate Finance LLP (Broker to the Company)   +44 (0)20 3470 0470

 David Hignell / Vadim Alexandre / Devik Mehta
 CPS Capital (Broker to A2A Pharmaceuticals)              +61 (0)8 9223 2222

 Jason Peterson / David Valentino
 Burson Buchanan (Public Relations)                       +44 (0)20 7466 5000

 Ben Romney / Jamie Hooper
 Peak IR (Investor Relations)                             +33 (0)7 44 44 15 42

 Seb Wykeham

 

LEI: ‎254900P4SISIWOR9RH34

 

For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com (http://www.roquefortplc.com) and @RoquefortTherap on X
(formerly Twitter)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUOUBRVSUKUAR